Scalper1 News
Biotech Isis Pharmaceuticals (ISIS) on Monday announced a licensing deal with German pharma giant Bayer (BAYRY) to develop Isis’ new thrombosis drug, sending its stock up as much as 6.8%. Bayer agreed to pay $100 million upfront and a $55 million milestone payment once Isis completes its phase-two study of ISIS-FXI Rx, an anticlotting drug being studied in patients with compromised kidney function. The company’s press release said it is eligible Scalper1 News
Scalper1 News